Menin Inhibitors vs FLT3 Inhibitor-Based Therapy in NPM1-Mutated Relapsed/Refractory AML: Comparative Efficacy, MRD Depth, and Safety Profiles (SOHO 2026) - Sep 1, 2026 - Abstract #AML-414; Location: LEVEL 3, HALL B3; "Interventions: MENi (revumenib, ziftomenib) targeting menin-KMT2A/HOXA signaling, and FLT3i-based regimens (gilteritinib monotherapy or combinations) targeting FLT3-driven signaling in relapsed/refractory AML. MENi and FLT3i-based regimens demonstrate comparable remission rates in NPM1-mutated relapsed/refractory AML but differ in response depth. MENi shows higher MRD negativity. FLT3i provides broader disease control with higher infectious burden, while MENi is associated with differentiation syndrome."
Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3 • KMT2A • NPM1
|
|
Hashem Haj Ebrahimi MD 1; Hiam Ghunaim MD 1; Fakriyeh Abachi Nejad Asl MD 2
|